retinopathy of prematurity (ROP)

Computer-based image analysis promising for ROPComputers may make more reliable diagnoses of plus disease in retinopathy of prematurity than individual clinicians, a researcher reports.
Novel software measures vessel tortuosity in ROPThe Novel Evidenced Assessment of Tortuosity (NEAT) system is intuitive and works even with poor images, according to its creators, Konstantinos Balaskas and his colleagues at Manchester Royal Eye Hospital and five other centres in the United Kingdom.
Could breast milk prevent blindness in premature infants?Retinopathy of prematurity—the leading cause of blindness in children—could be prevented with breast milk, according to a new report.
Identifying signs of congenital eye health problemsWhere does a visual impairment begin? Vision disorders can be influenced by a combination of genetic factors, environmental conditions, and lifestyle choices. When taking these into account, beginning with proper prenatal care is a good place to start.
Digital imaging screening may identify infants with referral-warranted ROPA telemedicine system for detecting retinopathy of prematurity in high-risk infants may help streamline examination and allow ophthalmologists to concentrate on those children with the greatest need.
Telemedicine catches ROP, NEI study findsA National Eye Institute (NEI) study found that telemedicine can effectively screen for retinopathy of prematurity (ROP) and could potentially ease the strain on hospitals with limited access to ophthalmologists.
Moran Eye Center publishes retinopathy of prematurity researchThe University of Utah’s John A. Moran Eye Center has published a research paper originating from the center examining the role of erythropoietin (EPO) signaling in retinopathy of prematurity (ROP) in the American Journal of Pathology.
Bevacizumab more cost-effective for ROP than laserTreating retinopathy of prematurity (ROP) has a great value in societal terms due to the potentially long lifespans ahead of these patients. However, a comparison of bevacizumab (Avastin, Genentech) and laser for treating ROP found that drug therapy was more cost effective than laser, even with extended follow-up periods, according to Michael J. Geske, MD.